source
- Mid-dose petrelintide shows strongest weight loss in phase-2 trial, paving way for pivotal studyRoche and Zealand Pharma released new phase-2 data for petrelintide, an amylin analog being developed for obesity treatment. In the Zupreme 1 trial, the 5 mg dose achieved the greatest mean weight…
- Trump administration's final Medicare pricing rule limits savings, covering only four firmsThe Trump administration released a final rule intended to lower Medicare prices for drugs administered in physician offices. The rule is part of the Global Benchmark for Efficient Drug Pricing (GL…